Background: Ranolazine is a late sodium current (late INa) inhibitor with anti-ischemic effects that is indicated for the treatment of stable angina. Patients with a history stable angina who subsequently are admitted with ACS are at particularly high risk of recurrent ischemic events. We examined the 1-year incidence of recurrent CV events in patients with prior angina who had PCI within 30 days of the index event and whether ranolazine offered any incremental benefit compared to placebo. Methods: 3565 patients in the MERLIN-TIMI 36 trial, which randomized patients with NSTE-ACS to ranolazine vs. placebo, reported a history of prior stable angina. The primary endpoint was the composite of CV death, MI, or recurrent ischemia (RI) defined as ischemia w/ ECG changes, leading to hospitalization, prompting revascularization, or worsening of stable angina prompting intensification of therapy. Results: In this cohort of patients with prior angina presenting with NSTEACS, 914 patients underwent PCI within 30 days of randomization. Overall, patients who underwent PCI had lower rates of CV death, but higher rates of RI and MI than patients who did not undergo PCI. Ranolazine reduced the risk of RI regardless of whether patients did or did not have PCI (21.3 v. 29.8%, HR 0.71, pϭ0.011 and 14.7 v. 18.2%, HR 0.81, pϭ0.03). Ranolazine significantly reduced the risk of the primary endpoint, CV death, and RI leading to revascularization in patients who underwent PCI, whereas there was no benefit among patients who did not undergo PCI.
Conclusions:
Regardless of whether patients underwent PCI or not for the treatment of ACS, ranolazine reduced the risk of recurrent ischemia during the 1 year following admission. In patients who did have PCI within 30 days of admission, rates of the primary endpoint and recurrent ischemia were lower in patients treated with ranolazine.
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Hall D Tuesday, October 23, 2012, 8:00 AM-10:00 AM Results: Compared with the dual group, the triple group had a similar incidence of major bleeding events but a significantly lower incidence of in-hospital mortality. MACE rate at 1 month was significantly higher in the dual group than that of triple (16.3 % vs. 11.1%, pϽ0.05), which was mainly due to death rather than re-PCI (12.9 % vs. 9.1%, pϽ0.05 Conclusions: There is a high prevalence of clopidogrel hyporesponsiveness in patients presenting with chest pain. Out of multiple potential risk factors, type II diabetes and black race were the strongest predictors of clopidogrel hyporesponsiveness, followed by gender and age.
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